Angelica Petrillo1,2, Elizabeth C Smyth3. 1. Medical Oncology Unit, Ospedale del Mare, Naples, Italy. 2. University of Study of Campania L. Vanvitelli, Naples, Italy. 3. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Abstract
BACKGROUND: Gastric cancer (GC) is one of the most lethal cancers worldwide. Although GC was historically considered a single entity within the organ of origin, nowadays it is acknowledged that GC represents a heterogeneous disease. Nevertheless, in this field there is still a lack of biomarkers able to guide the choice of the best treatment options for each patient. This review aims to summarize the prognostic and predictive biomarkers evaluated in GC and their role as a guide for treatment for precision medicine. SUMMARY: Human epidermal growth factor receptor 2 overexpression represents the only predictive molecular biomarker validated in GC, while its prognostic role is still controversial. Microsatellite instability and Epstein-Barr virus status are promising for prediction of the response to immunotherapy. The role of other biomarkers (ctDNA, programmed death ligand 1 [PD-L1], and TMB), as well as the practical application of molecular classifications, requires further evaluation before use in clinical practice. 18-FDG-PET scan could be useful as a predictive tool in non-metastatic GC patients receiving a perioperative approach. Finally, the tumor microenvironment may have an evolving role in the future. KEY MESSAGES: GC is a heterogeneous disease and targeted approaches are needed. The finding of prognostic and predictive factors is a hot topic in the field of GC personalized medicine.
BACKGROUND: Gastric cancer (GC) is one of the most lethal cancers worldwide. Although GC was historically considered a single entity within the organ of origin, nowadays it is acknowledged that GC represents a heterogeneous disease. Nevertheless, in this field there is still a lack of biomarkers able to guide the choice of the best treatment options for each patient. This review aims to summarize the prognostic and predictive biomarkers evaluated in GC and their role as a guide for treatment for precision medicine. SUMMARY: Human epidermal growth factor receptor 2 overexpression represents the only predictive molecular biomarker validated in GC, while its prognostic role is still controversial. Microsatellite instability and Epstein-Barr virus status are promising for prediction of the response to immunotherapy. The role of other biomarkers (ctDNA, programmed death ligand 1 [PD-L1], and TMB), as well as the practical application of molecular classifications, requires further evaluation before use in clinical practice. 18-FDG-PET scan could be useful as a predictive tool in non-metastatic GC patients receiving a perioperative approach. Finally, the tumor microenvironment may have an evolving role in the future. KEY MESSAGES: GC is a heterogeneous disease and targeted approaches are needed. The finding of prognostic and predictive factors is a hot topic in the field of GC personalized medicine.
Authors: J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: V Gambardella; J Castillo; N Tarazona; F Gimeno-Valiente; C Martínez-Ciarpaglini; M Cabeza-Segura; S Roselló; D Roda; M Huerta; A Cervantes; T Fleitas Journal: Cancer Treat Rev Date: 2020-03-23 Impact factor: 12.111
Authors: Yung-Jue Bang; Yoon-Koo Kang; Daniel V Catenacci; Kei Muro; Charles S Fuchs; Ravit Geva; Hiroki Hara; Talia Golan; Marcelo Garrido; Shadia I Jalal; Christophe Borg; Toshihiko Doi; Harry H Yoon; Mary J Savage; Jiangdian Wang; Rita P Dalal; Sukrut Shah; Zev A Wainberg; Hyun Cheol Chung Journal: Gastric Cancer Date: 2019-03-25 Impact factor: 7.370
Authors: Florian Lordick; Salah-Eddin Al-Batran; Manfred Dietel; Timo Gaiser; Ralf-Dieter Hofheinz; Thomas Kirchner; Hans H Kreipe; Sylvie Lorenzen; Markus Möhler; Alexander Quaas; Christoph Röcken; Josef Rüschoff; Andrea Tannapfel; Peter Thuss-Patience; Gustavo Baretton Journal: J Cancer Res Clin Oncol Date: 2017-03-11 Impact factor: 4.553
Authors: Csongor G Lengyel; Sadaqat Hussain; Andreas Seeber; Sara Jamil Nidhamalddin; Dario Trapani; Baker S Habeeb; Essam Elfaham; Syed Ayub Mazher; Fahmi Seid; Shah Z Khan; Khalid El Bairi; Andrew Odhiambo; Sara C Altuna; Angelica Petrillo Journal: Life (Basel) Date: 2022-01-07